In short
Clinical trials investigating Asparaginase are studying its role in treatment plans for acute lymphoblastic leukemia, especially in infants, children, and older adults. These studies look at outcomes such as survival, remission, and safety. They also compare Asparaginase-containing regimens with other treatment approaches.
Key points
- Clinical trials investigating Asparaginase are focused on acute lymphoblastic leukemia, which is a blood cancer. The studies include infants, children, and older adults, so the target groups are very different. The trial phases are mainly Phase 3 and Phase 4, which means the research is looking at how well treatment works and how safe it is in larger patient groups. One study measures event-free survival, another looks at minimal residual disease, and another compares event-free survival and overall survival. All of the listed trials are authorised and use Asparaginase within broader treatment plans.
Trial overview
The available studies are interventional trials, which means researchers are giving treatment plans and then measuring the results. All three trials are in acute lymphoblastic leukemia (ALL), a fast-growing blood cancer. Asparaginase is part of the treatment plans in these studies, but it is being tested as one element of a larger regimen, not alone.
Who is being studied
One trial studies infants under one year of age with newly diagnosed ALL, specifically KMT2A-rearranged infant ALL. Another trial includes children with ALL and confirmed activation of the JAK/STAT pathway, which is a cell-signaling pathway used to group patients for the study. The third trial focuses on older adults with newly diagnosed Philadelphia-negative B-cell precursor ALL.
These studies show that Asparaginase is being investigated across very different age groups. The trial data also show that the researchers are looking at special subgroups, not only all people with ALL.
Trial phases and study designs
The listed studies are in Phase 3 and Phase 4, which are later stages of clinical research. Phase 3 trials usually compare one treatment plan with another and measure how well they work. Phase 4 studies look at treatment use in a more real-world setting after earlier testing has already been done.
One trial includes a safety run-in, which is an early safety check before the main comparison starts. This helps researchers see whether the treatment plan is tolerable before they judge long-term outcomes.
What the trials measure
The infant ALL study uses event-free survival (EFS) as its main endpoint, which means the time from diagnosis until a major problem such as resistance to induction, relapse, death, or a second cancer. “Induction” is the first part of treatment, and resistance to induction means the leukemia does not go into complete remission by the end of that phase.
The JAK/STAT pathway study measures the proportion of patients who are MRD-negative at TP2, which means no minimal residual disease is found at that time point. MRD is a very small amount of leukemia that may remain even when standard tests show improvement.
The older-adult study measures safety in the run-in part, then compares event-free survival and overall survival in the main phase. Overall survival means the time from randomization until death from any cause.
Key trial details
NCT05327894 is a Phase 3, authorised study in 276 infants under one year with acute lymphoblastic leukemia, and its main goal is to improve event-free survival compared with historical results from the Interfant06 protocol.
2024-518316-39-00 is a Phase 4, authorised single-arm study in 25 children with ALL and confirmed JAK/STAT pathway activation, and it compares the MRD-negative rate at TP2 with an external control group. A single-arm study means there is no direct treatment comparison group inside the trial itself.
NCT04994717 is a Phase 3, authorised randomized study in 307 older adults with newly diagnosed Philadelphia-negative B-cell precursor ALL, and it compares blinatumomab alternating with low-intensity chemotherapy against standard chemotherapy. The study also includes safety outcomes such as treatment-emergent adverse events, treatment-related adverse events, and adverse events of interest in the safety run-in.
Important patient terms
Randomized means patients are assigned to different treatment groups by chance. External control means the study compares results with data from outside the trial rather than with a built-in control group. Historical results means past trial results are used as a comparison point.
Authorised means the study has been approved to move forward in the listed setting. Enrollment is the planned number of people who can take part in the study.